We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Micro-Lab on a Chip Detects Blood Type Within Minutes

By LabMedica International staff writers
Posted on 27 Jul 2020
Print article
Image: Schematic diagram of the fully-automatic blood-typing chip exploiting bubbles for quick dilution and detection (Photo courtesy of Tokyo University of Science).
Image: Schematic diagram of the fully-automatic blood-typing chip exploiting bubbles for quick dilution and detection (Photo courtesy of Tokyo University of Science).
Blood transfusion, if performed promptly, is a potentially life-saving intervention for someone losing a lot of blood. However, blood comes in several types, some of which are incompatible with others. Transfusing an incompatible blood type can severely harm a patient.

There are four major blood types, O, A, B, and AB. These types differ based on the presence or absence of structures called A antigens and B antigens on the surfaces of red blood cells. Blood can be further divided into positive and negative types based on the presence or absence of D antigens on red blood cells. Medical professionals usually tell a patient's blood type with tests involving antibodies against the A and B antigens.

Scientists at the Tokyo University of Science (Tokyo, Japan) developed a fully automated chip that can quickly and reliably determine a patient's blood type. The chip contains a micro-sized "laboratory" with various compartments through which the blood sample travels in sequence and is processed until results are obtained. To start the process, a user simply inserts a small amount of blood, presses a button, and waits for the result. Inside the chip, the blood is first diluted with a saline solution and air bubbles are introduced to promote mixing. The diluted blood is transported to a homogenizer where further mixing, driven by more intensely moving bubbles, yields a uniform solution.

Portions of the homogenized blood solution are introduced into four different detector chambers. Two chambers each contain reagents that can detect either A antigens or B antigens. A third chamber contains reagents that detect D antigens and a fourth chamber contains only saline solution, with no reagent, and serves as a negative control chamber in which the user should not observe any results. Antigen-antibody reaction will cause blood to agglutinate, and by looking at which chambers have hemagglutination, the user can tell the blood type and whether the blood is positive or negative. The team screened blood samples from 10 donors and obtained accurate results for all 10 samples. The time needed to determine a single sample's blood type was only five minutes.

Masahiro Motosuke, PhD, an associate professor and co-author of the study, said, “The advancement of simple and quick blood test chip technologies will lead to the simplification of medical care in emergency situations and will greatly reduce costs and the necessary labor on parts of medical staff.” The study was originally published online on April 14, 2020 in the journal Biomicrofluidics.

Related Links:
Tokyo University of Science

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Blood Gas and Chemistry Analysis System
Edan i500
New
Ultrasonic Cleaner
UC 300 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more